What is Zenflow?
Zenflow, Inc. operates at the intersection of medical device engineering and patient-centric urological care. Founded by Stanford University Biodesign Fellows, the company focuses on alleviating the symptoms of enlarged prostate through its innovative Spring system. Unlike traditional surgical interventions that may require invasive procedures, the Zenflow device utilizes a small, spring-like coil to gently support the urethra, effectively restoring natural function while preserving anatomical integrity. This approach represents a significant shift in the standard of care for benign prostatic hyperplasia, prioritizing patient comfort and recovery speed. By leveraging deep clinical insights from global urologists, Zenflow has established a robust intellectual property foundation that distinguishes its platform within the competitive healthtech landscape.
How much funding has Zenflow raised?
Zenflow has raised a total of $79.4M across 3 funding rounds:
Series A
$31.4M
Series B
$24M
Series C
$24M
Series A (2018): $31.4M with participation from Medical Technology Venture Partners, Invus Opportunities, and F-Prime Capital Partners
Series B (2021): $24M led by Medical Technology Venture Partners, Golden Seeds, Invus, F-Prime Capital Partners, Astia, SV Tech Ventures, and Cloudstone Capital
Series C (2024): $24M supported by F-Prime Capital Partners, Cook Medical, and Invus
Key Investors in Zenflow
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
Cook Medical
Cook Group Incorporated is an American privately held company based in Bloomington, Indiana, and primarily involved in manufacturing of medical devices.
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services, founded in 1985 and headquartered in New York City.
What's next for Zenflow?
The recent infusion of capital marks a pivotal milestone in Zenflow's growth trajectory, providing the necessary resources to navigate the final stages of regulatory approval and prepare for commercial scale. As the company moves forward, the strategic focus will likely center on expanding clinical trial data, refining manufacturing processes, and building the infrastructure required for a successful market launch. Given the backing of specialized healthcare investors, Zenflow is poised to disrupt the urology sector by offering a less invasive, highly effective alternative to existing treatment modalities. The company's ability to maintain consistent investor support from early-stage rounds through this major Series C financing suggests a high degree of institutional alignment regarding the long-term commercial viability of the Spring system.
See full Zenflow company page
